Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
International Vaccine Institute
ClinicalTrials.gov Identifier:
NCT01488188
First received: December 4, 2011
Last updated: November 5, 2013
Last verified: November 2013
  Purpose

Background: It is well established that live attenuated organisms can be highly effective vaccines, immune responses elicited can often be of greater magnitude and of longer duration than those produced by non-living antigens and are often able to confer protection after a single dose. Unlike killed influenza vaccine preparations injected by the parenteral route, live influenza vaccines are able to induce potent secretory (mainly IgA) antibody responses in the airway mucosae and can also evoke cell mediated responses. T cell proliferation, cytokine production, cytotoxic T cell responses and antibody-dependent cell cytotoxicity have all been elicited by live attenuated vaccines.

There has been a history of the use of live attenuated flu vaccines as safe and effective vaccines for the prevention of flu in animals and humans. Live-attenuated cold-adapted influenza vaccines have been proved to be highly efficacious to protect against clinical fly symptoms. Among these, FluMist, a nasal vaccine formulation developed by Medimmune Inc, has been approved by the US FDA. Recent side by side clinical trials have demonstrated that this nasal vaccine was significantly superior to conventional killed flu vaccine in protecting against flu symptoms.

Sublingual administration of live influenza virus at a dose lethal by the nasal route was well tolerated and did not redirect virus to the olfactory bulb. In addition, in a recent Phase I clinical study (NCT00820144) conducted in France, the sublingual administration of recombinant cholera toxin B subunit (rCTB,up to 1 mg) in healthy adult volunteers was found to be safe.

A major issue has arisen regarding the ease with which vaccines could be administered to young children, especially infants, and to elderly subjects in whom nasal vaccination has not been possible and/or approved due to difficulties of administering nasal vaccines in infants and to undesired side effects related to frequent rhinitis and sneezing episodes in elderly subjects. This study is designed to investigate the safety, tolerability and immunogenicity of a new route of administration of vaccines, using the nasal FluMist formulation as prototype vaccine.

Objectives: To evaluate the immunogenicity and safety of a nasal and sublingual influenza virus vaccine (FluMist) in healthy adult volunteers

Study design: This will be a randomized study on a total 40 subjects; each 20 subjects will receive vaccine via nasal and sublingual route, respectively


Condition Intervention Phase
Healthy
Biological: Influenza vaccine
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: A Controlled Study to Determine the Immunogenicity and Safety of Cold-adaptive Live Attenuated Influenza Vaccine (Flumist) Administered by the Nasal and Sublingual Route in Healthy Adult Volunteers

Resource links provided by NLM:


Further study details as provided by International Vaccine Institute:

Primary Outcome Measures:
  • Passive Haemagglutination Inhibition Titer. [ Time Frame: 21 days after vaccination ] [ Designated as safety issue: No ]
    Passive haemagglutination inhibition titer of serum at 21 days after vaccination.


Secondary Outcome Measures:
  • Blood Immunoglobulin G (IgG) and Immunoglobulin A (IgA)-Antibody Secreting Cell Number to Flu Virus [ Time Frame: 7 days after vaccination ] [ Designated as safety issue: No ]
    Flu virus-specific IgG- and IgA -antibody secreting cells per ml of blood at 7 days after vaccination

  • Salivary IgA [ Time Frame: 21 days after vaccination ] [ Designated as safety issue: No ]
    Salivary Flu-specific IgA titer at Days 21 after vaccination

  • Cell Mediated Immune Responses [ Time Frame: 21 days after vaccination ] [ Designated as safety issue: No ]
    Interferon gamma production in peripheral blood monocyte (PBMC) after in vitro re-stimulation with influenza virus antigen at 21 days after vaccination.


Enrollment: 40
Study Start Date: December 2011
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Influenza vaccine-Nasal
Nasal administration
Biological: Influenza vaccine
Administration of 1 dose (0.2 ml) by nasal route
Other Name: Flumist (2011-2012)
Active Comparator: Influenza vaccine -Sublingual
Sublingual administration
Biological: Influenza vaccine
Administration of 1 dose (0.2 ml) by sublingual route
Other Name: Flumist (2011-2012)

  Eligibility

Ages Eligible for Study:   20 Years to 49 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy volunteers who are able and willing to give informed consent, following a detailed explanation of participation in the study.
  • Volunteers who will be available for the duration of the study and available for scheduled and potential additional visits

Exclusion Criteria:

  • Subjects with any clinically significant medical or psychiatric condition or clinically significant abnormal serum biochemistry or haematology results that, in opinion of the Investigator, preclude participation in the study.
  • Female subjects who are pregnant (using urine test) or breast-feeding, or of childbearing potential and unwilling to use a reliable method of contraception (e.g. oral contraceptives or contraceptive during sexual activities such as a condom, contraceptive diaphragm, intrauterine device, hormonal contraceptive, or intercourse with a male partner who has had a vasectomy etc.) throughout the study period.
  • Subjects who have known airway hypersensitivity to one of Flu vaccine excipients within 14 days prior to administration of study medication.
  • Subjects who have known buccal hypersensitivity to any component of the vaccine or buffer solution used in this study, including subjects with phenylketonuria.
  • Subjects with direct contact with at risk groups (e.g. patients in special care units, immuno-compromised individuals, pregnant women, children under 2 years of age and individuals over 70 years).
  • Subjects with a known impairment of immune function including seropositive for HIV or those receiving (or have received in the 6 months prior to study entry) cytotoxic drugs immunosuppressive therapy (including systemic corticosteroids).
  • Subjects with a significant acute febrile illness (fever of 38.0 Celsius degree or more) at time of dosing.
  • Subjects who have chronic diseases: Chronic diseases will include all autoimmune and immuno-compromising conditions and any other chronic condition, which at the judgement of the Investigator, may put the subject at higher risk of side effects from the study vaccine. Conditions in the latter category might include unexplained anaemia, hepato-biliary disease, uncontrolled hypertension, subjects with prosthetic joints or heart valves, etc.
  • Subjects with a current problem, based on history, with substance abuse or with a history of substance abuse
  • Subjects who are currently involved in a clinical trial, have taken an investigational drug or have received investigational or licensed vaccines in the preceding 4 weeks or anticipate receiving a vaccine other than study medication during the first 4 weeks of the study
  • Subjects who have known hypersensitivity to eggs or egg proteins
  • Subjects who have chronic respiratory infections or syndromes
  • Unable to receive oral (sublingual) administration.
  • Receiving anti-viral agents.
  • Subjected to contraindications and/or precautions described in drug information
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01488188

Locations
Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of, 110744
Sponsors and Collaborators
International Vaccine Institute
Investigators
Principal Investigator: Kyung-Sang Yu, M.D. Seoul National University Hospital
Principal Investigator: Cecil Czerkinsky, Ph.D. International Vaccine Institute
  More Information

No publications provided

Responsible Party: International Vaccine Institute
ClinicalTrials.gov Identifier: NCT01488188     History of Changes
Other Study ID Numbers: FM-01 V1
Study First Received: December 4, 2011
Results First Received: July 31, 2013
Last Updated: November 5, 2013
Health Authority: Korea: Food and Drug Administration

Keywords provided by International Vaccine Institute:
Influenza vaccine
nasal route
sublingual route
immunogenicity
safety

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on September 14, 2014